Offer - Urjas Oil for just ₹ 1
Neugaba MN Tablet is an allopathic medicine The correct dosage of Neugaba MN Tablet depends on the patient's age, gender, and medical history. This information has been provided in detail in the dosage section.
Neugaba MN Tablet is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Is the use of Neugaba MN Tablet safe for pregnant women?
Neugaba MN Tablet is safe to take during pregnancy.
Is the use of Neugaba MN Tablet safe during breastfeeding?
Neugaba MN Tablet is completely safe for breastfeeding women.
What is the effect of Neugaba MN Tablet on the Kidneys?
Neugaba MN Tablet may cause harmful effects on kidney. if you feel its having any such effect, then stop taking this drug, and restart only on your doctor's advice.
What is the effect of Neugaba MN Tablet on the Liver?
Neugaba MN Tablet is rarely harmful for the liver.
What is the effect of Neugaba MN Tablet on the Heart?
Side effects of Neugaba MN Tablet rarely affect the heart.
Neugaba MN Tablet should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
If you are suffering from any of the following diseases, you should not take Neugaba MN Tablet unless your doctor advises you to do so -
Is this Neugaba MN Tablet habit forming or addictive?
Neugaba MN Tablet does not cause addiction.
Interaction between Food and Neugaba MN Tablet
Taking Neugaba MN Tablet with some specific foods may delay its effect. Talk to your doctor about this.
Interaction between Alcohol and Neugaba MN Tablet
Information about the interaction of Neugaba MN Tablet and alcohol is not currently available because this topic has not been researched yet.
This medicine data has been created by -
References
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 924-925
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Pamelor® (nortriptyline hydrochloride)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Lyrica (pregabalin)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1048-1049
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 420